Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study

Biomedical Chromatography

Volumn 29, Issue 8, 2015, Pages 1274-1279

  Ding, Xiao ^a   Salphati, Laurent ^a   Kim, Amy ^a   Morinello, Eric ^a   Wong, Lisa ^a   Pang, Jodie ^a   Percey, Shaundel ^b   Meng, Min ^b   Reuschel, Scott ^b   Dean, Brian ^a  

^a GENENTECH INC   (United States)

^b Northwest Toxicology Inc   (United States)

Author keywords

dual phosphatidylinositide 3 kinase mammalian target of rapamycin (PI3K mTOR) inhibitor; GDC 0980 (apitolisib); Good Laboratory Practice (GLP); LC MS MS; selected reaction monitoring

Indexed keywords

COLUMN CHROMATOGRAPHY; COPYRIGHTS; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

DOG PLASMA; DUAL PHOSPHATIDYLINOSITIDE 3-KINASE/MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; GDC-0980 (APITOLISIB); GOOD LABORATORY PRACTICE; LABORATORY PRACTICES; LC-MS-MS; LC.MS/MS; MAMMALIAN TARGET; SELECTED REACTION MONITORING; TARGET OF RAPAMYCIN;

ELECTROSPRAY IONIZATION;

APITOLISIB;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; GOOD LABORATORY PRACTICE; LIQUID CHROMATOGRAPHY; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; NONHUMAN; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; TOXICOKINETICS;

EID: 85006459395     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3417     Document Type: Article

References (9)

1. Benjamin D, Colombi M, Moroni C and Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Reviews: Drug Discovery 2011; 10: 868–880.
2. Chalhoub N and Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annual Reviews in Pathology 2009; 4: 127–150.
3. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews: Cancer 2009; 9: 550–562.
4. Gibaldi M and Perrier D. Pharmacokinetics. Marcel Dekker: New York, 1982.
5. Liu P, Cheng H, Roberts TM and Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery 2009; 8: 627–644.
6. Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S and Zhang X. Preclinical assessment of the absorption and disposition of the PI3K/mTOR inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metabolism and Disposition 2012; 40: 1785–1796.
7. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman AL, Goldsmith R, Gunzner J, Heffron T, Lesnick J, Lewis C, Mathieu S, Murray J, Nonomiya J, Pang J, Pegg N, Prior WW, Rouge L, Salphati L, Sampath D, Tian Q, Tsui V, Wan NC, Wang S, Wei B, Wiesmann C, Wu P, Zhu BY and Olivero A. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. Journal of Medicinal Chemistry 2011; 54: 7579–7587.
8. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001. http://www.fda.gov/
9. Wong KK, Engelman JA and Cantley LC. Targeting the PI3K signaling pathway in cancer. Current Opinion in Genetic Development 2010; 20: 87–93.